You're dealing with urgent biotech manufacturing demands. How do you decide where to allocate your resources?
Facing biotech resource puzzles? Dive in and share your strategies for tackling urgent allocation decisions.
You're dealing with urgent biotech manufacturing demands. How do you decide where to allocate your resources?
Facing biotech resource puzzles? Dive in and share your strategies for tackling urgent allocation decisions.
-
En la fabricación de biotecnología, las demandas urgentes requieren decisiones rápidas y estratégicas sobre la asignación de recursos. En primer lugar, evalúo las prioridades según el impacto en la producción y los plazos críticos, asegurándome de que los proyectos de mayor valor o que aborden necesidades inmediatas reciban los recursos necesarios. Al mismo tiempo, analizo la capacidad del equipo y la disponibilidad de materiales para evitar cuellos de botella. Además, mantener una comunicación abierta con los equipos involucrados me permite ajustar las asignaciones en tiempo real, garantizando una respuesta ágil y eficaz.
-
Urgent biotech manufacturing reallocations require trade-offs along multiple dimensions: Consider whether this urgent demand has strategic benefits which outweigh any operational issues. For example, if an additional batch is needed, will this support the start (!) of the approval process in a new market (strategic), or should it be kept to support the finish (!) of an running clinical trial which would bring in revenue (rather operational). Often a swap of resources affects existing customers/ markets through delays or material availability. These customers need to be identified and mitigation options (e.g. for material cannibalization, labor and capacity) explored. And, speed of decision making is often more important than granularity.
Rate this article
More relevant reading
-
BiotechnologyDealing with biotech manufacturing delays is tough. How can you keep stakeholders informed and engaged?
-
Laboratory ManagementHere's how you can effectively convey the advantages of new technology to laboratory stakeholders.
-
BiotechnologyWhat are the best practices for conducting due diligence on biotech partners?
-
SustainabilityWhat are the most effective ways to overcome supply chain disruptions in the pharmaceutical industry?